AZothBio is a company that develops new drugs and drug delivery vehicles based on an AI platform.

The new drug development AI platform (iSTAs) built by AZothBio is a MoliSTA platform designed to express 3D molecular structures in drug candidates, target genes, and efficacy information using statistical thermodynamics, and is capable of predicting cell penetration ability and creating new structures. It consists of the DDiSTA platform and ArchiSTA, a DATA integrated management platform.

We are conducting joint research with various pharmaceutical/bio companies using iSTAs built with our own technology, and are developing our own small molecule therapeutics (autoimmune disease therapeutics, anti-cancer therapeutics) and cell-permeable drug delivery vehicle peptides.

Peptide-based drug delivery vehicles targeting intracellular organelles developed based on DDiSTA are designed to selectively deliver nucleic acids (DNA, mRNA, siRNA, etc.) or small molecule substances to intracellular organelles.

AZothBio is conducting research to expand its application areas to immune disease therapeutics, gene therapy, and inflammation therapeutics based on drug delivery vehicles.

By utilizing AZothBio’s AI platform, you can very efficiently reduce the costs and time required for drug discovery.